Mucinous adenocarcinoma of the appendix

Summary

Mucinous adenocarcinoma of the appendix (MONDO:0018330) is a disease and 1 clinical trial. Top therapeutic interventions include ipilimumab. A subtype of colon mucinous adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mucinous adenocarcinoma of the appendix
Mondo ID	MONDO:0018330
Orphanet	391723
ICD-11	425095558
NCIT	C43558
UMLS	C1706832
MedGen	317382
GARD	0021629
Anatomy (UBERON)	UBERON:0001154
Is cancer (heuristic)	no

Also known as: appendiceal mucinous adenocarcinoma · appendix mucinous adenocarcinoma · vermiform appendix mucinous adenocarcinoma

Disease family

This is a subtype of colon mucinous adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › colonic disorder › colonic neoplasm › malignant colon neoplasm › colon carcinoma › colon adenocarcinoma › colon mucinous adenocarcinoma › mucinous adenocarcinoma of the appendix

Subtypes (2): appendix mucinous cystadenocarcinoma, pseudomyxoma peritonei

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IPILIMUMAB	4	1